Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in STRASBOURG, Alsace – page 80

990 clinical trials in STRASBOURG, Alsace, France across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
STRASBOURG, Alsace at a glance
990
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

990 trials in STRASBOURG, Alsace

Open in trial search

Endometrial cancer

Not recruiting

Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide
  • Sponsor:Kartos Therapeutics Inc.

Breast cancer metastatic

Not recruiting

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Unicancer

Prostate cancer recurrent

Not recruiting

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Tourette's disorder

Not recruiting

Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette's Disorder

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ecopipam Hydrochloride
  • Sponsor:Emalex Biosciences Inc.

Acute coronary syndrome

Not recruiting

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Primary biliary cholangitis

Not recruiting

Study on Volixibat for Treating Itching in Patients with Primary Biliary Cholangitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Volixibat
  • Sponsor:Mirum Pharmaceuticals Inc.

Head and neck cancer

Not recruiting

Study of Radiotherapy with Cetuximab and Xevinapant for Patients with Advanced Head and Neck Cancer Unfit for High-Dose Cisplatin

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Non-Clear Cell Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Hepatic encephalopathy

Not recruiting

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rifaximin
  • Sponsor:Salix Pharmaceuticals Inc.

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Dementia Alzheimer's type

Not recruiting

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Biogen Idec Research Limited

Hodgkin's disease

Not recruiting

Study of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in STRASBOURG, Alsace

What the registry says about research in the country

01 Oncology Research

Advanced studies focusing on head and neck cancers, bladder cancer, and multiple myeloma. Novel therapeutic approaches combining immunotherapy with established treatments are being evaluated for improved patient outcomes.

  • EGFR-targeted therapies for head and neck cancer
  • Non-muscle invasive bladder cancer treatment
  • Multiple myeloma consolidation therapy

Innovative combination therapies are being tested to enhance treatment efficacy while maintaining patient safety.

02 Neurological Disorders

Comprehensive research into multiple sclerosis, essential tremor, and ADHD. Studies are evaluating both new and existing medications for improved symptom management and disease control.

  • Multiple sclerosis treatment strategies
  • Essential tremor therapeutic interventions
  • ADHD neural mechanism studies

Advanced neuroimaging techniques are being utilized to understand treatment effects on brain circuits.

03 Autoimmune Conditions

Investigating new treatments for Crohn's disease, Sjögren's Syndrome, and Myasthenia Gravis. Research focuses on innovative therapeutic approaches including microbiota transplantation and targeted immunotherapies.

  • Fecal microbiota transplantation studies
  • Novel antibody treatments
  • Immunomodulatory therapies

These trials aim to improve disease management and patient quality of life through targeted interventions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.